First Time Loading...

Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.39 USD 3.73% Market Closed
Updated: May 5, 2024

Inhibikase Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inhibikase Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Inhibikase Therapeutics Inc
NASDAQ:IKT
Operating Income
-$20.1m
CAGR 3-Years
-92%
CAGR 5-Years
-57%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Inhibikase Therapeutics Inc's Operating Income?
Operating Income
-20.1m USD

Based on the financial report for Dec 31, 2023, Inhibikase Therapeutics Inc's Operating Income amounts to -20.1m USD.

What is Inhibikase Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-57%

Over the last year, the Operating Income growth was -11%. The average annual Operating Income growth rates for Inhibikase Therapeutics Inc have been -92% over the past three years , -57% over the past five years .